TG Therapeutics, Inc.
TGTX
Classement en actions
#2403
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Prix de l'action
$53.19
Capitalisation boursière
$8.14B
Changement (1 jour)
-2.46%
Changement (1 an)
51.02%
Pays
US
Échange TG Therapeutics, Inc. (TGTX)
Catégorie
Healthcare
Ratio P/E pour TG Therapeutics, Inc. (TGTX)
Ratio P/E au October 2026 TTM : 17.86
Selon les derniers rapports financiers et le cours de l'action de TG Therapeutics, Inc., le ratio P/E actuel (TTM) est de 17.86. À la fin de l’année 2023, le P/E de l’entreprise était de 191.33.
Historique du ratio P/E pour TG Therapeutics, Inc. de 2000 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 17.86 | -90.45% |
| 2024 | 187.06 | -2.23% |
| 2023 | 191.33 | -2,468.94% |
| 2022 | -8.08 | 11.91% |
| 2021 | -7.22 | -66.39% |
| 2020 | -21.47 | 278.47% |
| 2019 | -5.67 | 218.13% |
| 2018 | -1.78 | -58.48% |
| 2017 | -4.30 | 47.42% |
| 2016 | -2.91 | -66.31% |
| 2015 | -8.65 | -10.58% |
| 2014 | -9.67 | 99.88% |
| 2013 | -4.84 | 83.25% |
| 2012 | -2.64 | 3.52% |
| 2011 | -2.55 | -179.01% |
| 2010 | 3.23 | -259.65% |
| 2009 | -2.02 | 52.83% |
| 2008 | -1.32 | 192.68% |
| 2007 | -0.45 | -8.83% |
| 2006 | -0.50 | 172.53% |
| 2005 | -0.18 | -50.21% |
| 2004 | -0.37 | 21.63% |
| 2003 | -0.30 | -53.56% |
| 2002 | -0.65 | 339.61% |
| 2001 | -0.15 | 771.01% |
| 2000 | -0.02 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | 61.19% |
US
|
|
| -28.36 | -258.82% |
US
|
|
| -24.57 | -237.58% |
AU
|
|
| 30.33 | 69.86% |
NL
|
|
| - | - |
CH
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.